Articles tagged with Ovarian Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
Researchers have identified nine new factors involved in DNA repair, a critical process for human cell health. The findings can help develop new cancer drugs and improve existing therapies.
Four MUSC Hollings Cancer Center researchers received American Cancer Society Institutional Research Grants worth $35,000 each. The grants support promising projects that aim to push cancer care forward. Researchers are working on various innovative projects, including a digital literacy training program for community health workers an...
The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.
Researchers have discovered that ovarian cancer begins with cancerous lesions in the fallopian tube linings of women with BRCA-1 mutations. The study's findings hold promise for predicting which women will develop ovarian cancer years or decades in advance, allowing for early detection and prevention strategies.
A study of over 200,500 women found an increased risk of death in younger pre-menopausal women when ovaries and fallopian tubes were removed during surgery. In contrast, the procedure is safer for older post-menopausal women, whose ovaries have already stopped producing estrogen.
Researchers at Hokkaido University analyzed hundreds of women with ovarian granulosa cell tumors to improve understanding of the disease progression and response to therapy. They found that early-stage tumors rarely spread beyond the ovaries, and fertility-sparing surgery may be considered for younger patients.
Scientists used single-cell sequencing to analyze over 150,000 cells from 11 tumor samples, discovering novel mechanisms of tumor development and identifying potential targets for therapy. The findings may lead to personalized medicine and improved treatment options for gynecologic cancers.
Researchers at The Wistar Institute have identified genes that help ovarian cancer evade the immune system. These findings could lead to more effective immunotherapy for ovarian and other types of cancer.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers at the University of Copenhagen have discovered that the BRCA2 gene requires a specific enzyme, PP2A-B56, to repair DNA damage. This finding may pave the way for more targeted treatment of cancer patients with certain mutations.
A Korean population-based cohort study found that cancer, particularly multiple myeloma and leukemia, is associated with an increased risk of kidney failure. The study included approximately 825,000 patients with cancer compared to twice as many without cancer, matched on other characteristics.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Researchers found that microscopic defects in healthy cell alignment can slow down tumor cell invasion. The study used an experimental model to show how topological defects affect the rate of tumor cell invasion, with certain defects causing cancer cells to pass through the barrier more slowly.
Researchers identified mono(ADP-ribose) and NMNAT-2 as potential biomarkers for ovarian cancers, enabling clinicians to determine which patients may respond well or poorly to treatment. The discovery also highlights a selective advantage that can be exploited to inhibit cancer growth.
Researchers have discovered a new group of patients who are likely to benefit from PARP inhibitor therapy, which has shown unprecedented success in treating BRCA1/2 mutated cancers. The study identified tumours with epigenetic marks that silenced the RAD51C gene, making them sensitive to PARP inhibitors.
Mayo Clinic researchers used advanced imaging technology to visualize the BRCA1-BARD1 protein complex and its interaction with chromatin. The study provides new insights into how BRCA1-BARD1 functions, which could lead to improved cancer prevention efforts and drug development.
Researchers at Texas A&M University have developed an organ-on-a-chip that models the interaction between platelets and ovarian cancer tumors, revealing a crucial genetic signaling pathway. This breakthrough technology has potential applications in observing how cancer cells interact with blood vessels and testing novel treatments.
A world-first AI study will map genetic and physical risks of ovarian cancer based on UK Biobank data. The project aims to identify biomarkers for early detection and improve survival rates.
Ovarian cancer is the most lethal gynaecological cancer with an absence of screening programmes, leading to late diagnosis and poor prognosis. Despite targeted therapies, personalized medicine remains a challenge due to inconsistent symptoms and resistance to chemotherapy.
The company's 3D Predict assay has been validated for predicting responses to temozolomide in glioblastoma patients, with predictive accuracy comparable to its previous results in ovarian cancer. The test identifies future responders and non-responders, enabling personalized treatment strategies.
A new study published in Proceedings of the National Academy of Sciences suggests that surgery should precede chemotherapy for certain patients with ovarian cancer. The research used a mathematical model to examine treatment outcomes and found that complete debulking surgery followed by chemotherapy provides better results. For patient...
A new radiopharmaceutical has been developed to treat ovarian cancer, dramatically limiting tumor growth and decreasing tumor mass. The treatment, which can be produced in just 25 minutes at low cost, shows promise as an efficient alternative to existing methods.
A Penn-developed odor test using AI and machine learning distinguishes between cancer cells and benign tumors in blood samples. The tool achieves high accuracy rates for detecting ovarian and pancreatic cancers, showing promise as a non-invasive screening approach.
Researchers from NUS Cancer Science Institute have discovered a link between high levels of DNA repair protein RAD51 and platinum chemotherapy resistance in ovarian cancer patients. This finding could help identify patients who may require novel immunotherapy approaches to improve treatment outcomes.
A new study reveals that breast cancer survivors have a 20-44% higher risk of developing new cancer diagnoses compared to healthy individuals. The research identifies specific breast cancer subtypes and diagnosis ages associated with increased risk of subsequent primary cancers.
A large-scale trial of annual screening for ovarian cancer found that neither method reduced deaths from the disease, contradicting expectations. Early detection strategies detected cancers earlier, but this did not translate into saving lives.
A study published in Nature Communications found that rucaparib is effective in treating ovarian cancers with inherited or somatic mutations in DNA repair genes. The drug targets the Achilles heel of cancers with defects in DNA repair, outperforming chemotherapy in early treatment stages.
The UK Markey Cancer Center has launched a clinical trial to evaluate the anti-cancer activity of ArtemiLife coffee products in preventing ovarian cancer recurrence. Participants will drink coffee up to four times daily for five months after completing treatment, aiming to delay or eliminate cancer return.
A new study published in Diagnostics demonstrates that artesunate, a drug synthesized from Artemisia annua, kills ovarian cancer cells. The researchers found anticancer activity at achievable concentrations, supporting the clinical development of this strategy.
Researchers at McMaster University have discovered a new approach to training immune cells to fight cancer, which has shown promising results in overcoming the hostile conditions found inside solid tumours. The modified natural killer cells were able to destroy advanced ovarian and lung cancer with high effectiveness.
Researchers from MD Anderson Cancer Center present promising results on RET fusion-positive cancers, HGG, LGG, and ovarian cancer. The FDA-approved selpercatinib shows clinical benefits in preventing or inhibiting tumor growth beyond lung and thyroid cancers.
A recent study found that end-of-life care for people with ovarian cancer has not improved significantly since 2007, with Black patients experiencing higher rates of emergency department visits and intensive treatment. Palliative care recommendations have been included in guidelines, but its adoption remains limited.
Australian researchers have made a world-first discovery in targeting an aggressive childhood cancer, neuroblastoma. They found that the cellular protein ALYREF plays a crucial role in accelerating MYCN-driven cancer growth in neuroblastoma cells.
Golfers Against Cancer funds three CU Cancer Center researchers: Matthew Sikora studying genetic predispositions to ovarian cancer, Jamie Studts exploring lung cancer screening access, and Jenna Sopfe developing a standardized approach to sexual dysfunction in pediatric cancer survivors.
Researchers have identified a previously unknown dual function of polymerase theta (pol theta) in DNA repair, which could lead to the development of new therapeutic options for breast and ovarian cancers. The finding shows pol theta can both extend DNA and trim it, making it a potential target for treatment development.
A study by Queen Mary University researchers investigated how women at high risk of ovarian cancer make choices about possible preventive surgery. Women who have BRCA1 and BRCA2 genetic mutations have a higher lifetime risk of ovarian cancer, and may choose to undergo surgery to reduce their risk.
A new study from the University of Minnesota Medical School found that Pap test samples can detect proteins also present in ovarian cancer tumor tissues. This discovery suggests potential biomarker candidates for early detection of ovarian cancer, which currently has no early warning system.
The European Union has funded a project to develop diagnostic tools and combination treatments for ovarian cancer using AI. The research aims to identify patients whose cancer is not responding to current treatments and discover effective, personalized therapies.
Researchers found that antibodies produced by B cells predominantly have the IgA subtype, which inhibits RAS signaling, sensitizing tumor cells to T cell-mediated killing. This study provides insights into how immune components regulate ovarian cancer progression and offers new approaches for targeted immunotherapies.
This study elucidates the molecular mechanism of 2-methoxyestradiol (2MeOE2) inducing apoptosis in ovarian tumors through PKCδ signaling. The findings suggest that 2MeOE2 activates PKCδ, leading to γH2Ax expression and apoptotic histone modifications, thereby driving apoptosis in ovarian cancer cells.
Researchers discovered that ovarian cancer cells undergo structural changes in their mitochondria to survive and proliferate in the peritoneal cavity. This adaptation enables aggressive cancerous cells to grow and spread, making it harder to detect and treat. Understanding these cellular adaptations could lead to new targeted therapies.
Mutations in the ARID1A gene increase glutamine metabolism in ovarian cancer cells, which can be blocked to target ARID1A-mutant tumors. Glutaminase inhibitors like CB-839 show promise as a standalone or combination therapy for clear cell ovarian carcinoma.
A new advanced computing technique enables doctors to take fewer, more accurate tumour biopsies by combining computed tomography (CT) scans with ultrasound images. This method captures the patchwork of different cancer cell types within a tumour, critical for selecting the best treatment.
A comprehensive study of over 250,000 women found oral contraceptives significantly reduce the risk of ovarian and endometrial cancer, with benefits persisting even years after use ends. The findings contradict previous associations with increased breast cancer risk.
Researchers at Tel Aviv University developed a CRISPR-Cas9 system that specifically targets cancer cells, destroying them by genetic manipulation. The system improved the average life expectancy of mice with glioblastoma tumors by 30% and increased overall survival rate in metastatic ovarian cancer mice model by 80%.
A new study published in JNCI: Journal of the National Cancer Institute indicates that receiving assisted reproductive technology does not increase the risk women have for developing ovarian cancer. While fertility treatments may slightly increase borderline ovarian tumor risk, this association appears to be due to underlying patient c...
Population-wide screening of 30-year-old women resulted in 75 fewer cancer cases per 100,000 women, with a gain of 288 quality-adjusted-life-years compared to 97 for women aged 45.
Scientists have created a 3D tumour model for ovarian cancer, which can mimic the way tumour cells grow and respond to chemotherapy drugs. The new model has the potential to improve understanding and treatment of the disease.
This observational study examines survival rates and chemotherapy use before surgery in US women with advanced ovarian cancer between 2004-2016. The study found improvements in treatment and survival rates over time, with more patients receiving chemotherapy before surgery.
Researchers from CU published a paper on ovarian cancer tumor composition changes during chemotherapy, revealing potential biomarkers for therapeutic response. The team aims to improve prediction of patient response to chemotherapy using multi-spectral immunohistochemistry and transcriptomics.
Researchers at the University of Turku developed a rapid point-of-care diagnostic test to detect ovarian cancer from blood samples in 30 minutes. The new test shows improved sensitivity and accuracy compared to conventional CA125 diagnostics.
Scientists at Cornell University's veterinary college have identified the genetic drivers of ovarian cancer, a deadly disease that kills more women than any other cancer. The study reveals that ovarian surface stem cells are more susceptible to mutations, while certain genes can inhibit cancer initiation.
Researchers found GATA3 and APOBEC3B overexpressed in adrenocortical carcinoma, regulating cell proliferation and DNA damage. Their expression levels are linked to patient survival, providing novel insights into ACC prognosis.
Researchers found a slight increase in risk of ovarian cancer and some types of breast cancer among women who used permanent hair dyes. Natural hair color was also associated with an increased risk of certain cancers, while the use of darker hair dye colors may be linked to higher concentrations of ingredients.
Researchers have identified a metabolic vulnerability in cells that may represent a therapeutic target for treating small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). A new treatment agent has been shown to starve cancer cells by eliminating arginine, an amino acid necessary for protein production.
A new two-stage surgical protocol delays the induced menopause caused by ovary removal, providing some ovarian cancer risk reduction while avoiding detrimental consequences. The study found that 69% of premenopausal women at high risk of ovarian cancer were interested in this alternative option.
Researchers developed a tumour gene test that accurately predicts ovarian cancer survival, outperforming age and cancer stage. The test identifies high-risk patients for personalized treatment options.
A CUNY ISPH study reveals that ovarian cancer grows and evolves continuously, with mixtures of subclones accumulating mutations. The findings challenge previous simplistic models of discrete subtypes, offering a clearer picture of tumor heterogeneity.